Mario Corso
Recent Quotes
"We expect FDA approval of ACRX's Zalviso at/near the July PDUFA date."
—
Mario Corso, Mizuho Securities
(1/16/14)
more >
"ACRX is a rare, undervalued company targeting a $1B market."
—
Mario Corso, Mizuho Securities
(1/6/14)
more >
Due to permission requirements, not all quotes are shown.
